Enveric Biosciences Divests Cancer-Targeting Cannabinoid IP to Focus on Mental Health Therapeutics

26 February 2024 | Monday | News

The strategic sale marks a pivotal shift towards advancing novel treatments for depression, anxiety, and addiction disorders.
Image Source : Public Domain

Image Source : Public Domain


Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology firm at the forefront of developing neuroplastogenic small-molecule therapeutics, announced a strategic move to sell its cancer-targeting cannabinoid-related intellectual property (IP). This decision underscores the company's commitment to concentrate efforts and resources on its innovative neuroplastogenic molecules, EB-003 and EB-002, aimed at treating mental health disorders such as depression, anxiety, and addiction.

The divested patent portfolio encompasses a synergistic combination of cannabidiol (CBD) with second therapeutic agents for cancer treatment, including patents issued across the globe in major markets such as the U.S., Australia, Canada, China, Europe, and Japan, along with pending applications in Canada, Israel, and Korea. Following the sale, Enveric will relinquish all ownership rights over the divested assets, empowering the undisclosed buyers to further the research, clinical development, and potential commercialization of CBD-based cancer therapies.

Joseph Tucker, Ph.D., CEO and Director of Enveric, expressed enthusiasm about the divestiture, emphasizing the unlocked value from the cannabinoid-related IP and its alignment with the company's strategic focus on mental health therapeutics. "This transaction enables Enveric to intensify our development of EB-003 and EB-002, while providing a solid foundation for our purchasers to explore cannabidiol-based cancer treatments," stated Tucker.

Enveric's dedication to mental health innovation is further highlighted by the recent introduction of a promising library of novel preclinical compounds, encompassing psilocybin derivatives, psilocybin prodrugs, and derivatives of mescaline and MDMA. These compounds represent the company's ongoing efforts to discover, develop, and potentially out-license or partner groundbreaking therapies in the mental health domain.

The announcement not only reflects Enveric's strategic realignment but also its capability to generate value through the discovery and development of preclinical assets and the construction of a robust intellectual property portfolio. With this divestiture, Enveric Biosciences continues to pave the way for groundbreaking advancements in the treatment of mental health disorders, while facilitating the exploration of cannabinoid-based cancer therapies by its industry partners.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in